Autor: |
Guozhong Jiang, Zhizhong Wang, Zhenguo Cheng, Weiwei Wang, Shuangshuang Lu, Zifang Zhang, Chinedu A. Anene, Faraz Khan, Yue Chen, Emma Bailey, Huisha Xu, Yunshu Dong, Peinan Chen, Zhongxian Zhang, Dongling Gao, Zhimin Wang, Jinxin Miao, Xia Xue, Pengju Wang, Lirong Zhang, Rathi Gangeswaran, Peng Liu, Louisa S. Chard Dunmall, Junkuo Li, Yongjun Guo, Jianzeng Dong, Nicholas R. Lemoine, Wencai Li, Jun Wang, Yaohe Wang |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024) |
Druh dokumentu: |
article |
ISSN: |
2041-1723 |
DOI: |
10.1038/s41467-024-53164-x |
Popis: |
Abstract Esophageal squamous cell carcinoma (ESCC) is highly heterogeneous. Our understanding of full molecular and immune landscape of ESCC remains limited, hindering the development of personalised therapeutic strategies. To address this, we perform genomic-transcriptomic characterizations and AI-aided histopathological image analysis of 120 Chinese ESCC patients. Here we show that ESCC can be categorized into differentiated, metabolic, immunogenic and stemness subtypes based on bulk and single-cell RNA-seq, each exhibiting specific molecular and histopathological features based on an amalgamated deep-learning model. The stemness subgroup with signature genes, such as WFDC2, SFRP1, LGR6 and VWA2, has the poorest prognosis and is associated with downregulated immune activities, a high frequency of EP300 mutation/activation, functional mutation enrichment in Wnt signalling and the highest level of intratumoural heterogeneity. The immune profiling by transcriptomics and immunohistochemistry reveals ESCC cells overexpress natural killer cell markers XCL1 and CD160 as immune evasion. Strikingly, XCL1 expression also affects the sensitivity of ESCC cells to common chemotherapy drugs. This study opens avenues for ESCC treatment and provides a valuable public resource to better understand ESCC. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|